Edwards Lifesciences Outlines Patient-Focused Strategy for Sustainable Growth, Sets Financial Guidance for 2026

Edwards Lifesciences reaffirms its strategy for sustainable, differentiated growth, with a focus on patient-focused innovations for structural heart diseases. The company outlines financial guidance for 2026, including 8%-10% constant currency sales growth and adjusted EPS of $2.80-$2.95. Edwards projects TAVR sales of $4.6-$4.9 billion, TMTT sales of $740-$780 million, and surgical sales of $1.05-$1.13 billion. The company also highlights its expanding structural heart portfolio, targeting 10% average annual constant currency sales growth.